Applied Therapeutics Management

Management criteria checks 1/4

Applied Therapeutics' CEO is Les Funtleyder, appointed in Nov 2023, has a tenure of 1.17 years. directly owns 0.11% of the company’s shares, worth €90.58K. The average tenure of the management team and the board of directors is 1.1 years and 5.8 years respectively.

Key information

Les Funtleyder

Chief executive officer

US$675.2k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.2yrs
CEO ownership	0.1%
Management average tenure	1.1yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO

Les Funtleyder (54 yo)

1.2yrs

Tenure

US$675,150

Compensation

Mr. Les D. Funtleyder served as Interm CEO, CFO, Principal Financial Officer & Independent Director of Applied Therapeutics, Inc. from December 20, 2024. He was CFO, Principal Financial Officer & Independe...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Les Funtleyder	Interm CEO	1.2yrs	US$675.15k	0.11% € 90.6k
Riccardo Perfetti	Chief Medical Officer	6.4yrs	US$3.04m	0.14% € 119.3k
John Johnson	Executive Chairman	less than a year	no data	no data
Constantine Chinoporos	COO & Chief Business Officer	1.1yrs	no data	no data
Catherine Thorpe	Chief Accounting Officer	1.6yrs	no data	no data
Corwin Hooks	Chief Commercial Officer	less than a year	no data	no data

1.1yrs

Average Tenure

59yo

Average Age

Experienced Management: 2UV's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Les Funtleyder	Interm CEO	8.6yrs	US$675.15k	0.11% € 90.6k
John Johnson	Executive Chairman	less than a year	no data	no data
Jay Skyler	Independent Director	5.8yrs	US$92.53k	0.017% € 14.2k
Lawrence Steinman	Member of Scientific Advisory Board	no data	no data	no data
Teena Lerner	Lead Independent Director	7.8yrs	US$88.78k	0.052% € 42.8k
Stacy Kanter	Independent Director	5.7yrs	US$94.40k	0.054% € 44.6k
Gregg Stone	Member of Scientific Advisory Board	no data	no data	no data
Donald Landry	Chairman of Scientific Advisory Board	no data	no data	no data
Donald D'Amico	Member of Scientific Advisory Board	no data	no data	no data
Roy Freeman	Member of Scientific Advisory Board	no data	no data	no data
Roxana Mehran	Member of Scientific Advisory Board	no data	no data	no data

5.8yrs

Average Tenure

67yo

Average Age

Experienced Board: 2UV's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 20:58
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Applied Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Carter Gould	Barclays
Catherine Seifert	CFRA Equity Research

Applied Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Chief Medical Officer recently sold €119k worth of stock

Chair of the Board of Directors recently sold €4.3m worth of stock

Chair of the Board of Directors recently sold €245k worth of stock

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Recent updates

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Robbins Geller Rudman & Dowd LLP Announces That Applied Therapeutics, Inc. Investors with Substantial Losses Has Opportunity to Lead the Applied Therapeutics Class Action Lawsuit

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

New major risk - Financial position

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

Chief Medical Officer recently sold €119k worth of stock

Chair of the Board of Directors recently sold €4.3m worth of stock

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Share price stability

Chair of the Board of Directors recently sold €245k worth of stock

New minor risk - Profitability

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold €1.6m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Insufficient new directors

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought €60k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

New major risk - Shareholder dilution

New major risk - Financial position

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Insufficient new directors

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources